Individuals with a rare form of epilepsy treated with fenfluramine experienced significantly greater seizure reduction as ...

The biotech sector staged a robust comeback in 2025, with the Nasdaq Biotechnology Index climbing 33.8%. Although concerns ...

For patients with relapsed or refractory multiple myeloma, treatment with teclistamab plus daratumumab is associated with a significant PFS benefit.

Doctors are urging San Diegans to not ignore their heart health during the holidays, as research shows this time of year ...

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Trodelvy showed fewer severe side effects, such as neutropenia and diarrhea, compared to chemotherapy in untreated TNBC ...

Combination therapy with a nonsteroidal mineralocorticoid receptor antagonist and an SGLT2 inhibitor reduced albuminuria more ...

The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...

Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...

Based on the positive global Phase III MANEUVER study, the National Medical Products Administration (NMPA) has granted the world’s first regulatory approval for pimicotinib, the first domestically ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMFDA Approval Based on ...